Skip to main content

Legal Capsule by LexCounsel


Telemedicine Practice through Consultation Centres/Clinics in

 India: Guidelines and Regulatory Approvals 

Onset of COVID 19 pandemic created an urgency in provision of medical services to remote areas through digital and online means and adoption of technology. Prior to March 25, 2020, there was no single consolidated regulation or guideline in India which dealt with the practice of telemedicine. Telemedicine was accordingly governed by the same statutes that govern the ‘practice of medicine’ in India such as Indian Medical Council Act, 1956 (as superseded by the National Medical Commission Act, 2019, the “IMC Act”) and the subsequent rules and regulations issued thereunder.


Telemedicine Practice Guidelines


The Ministry of Health and Family Welfare on March 25, 2020 issued the Telemedicine Practice Guidelines (“Guidelines”) for enabling Registered Medical Practitioners1 (“RMPs”) to provide healthcare using telemedicine. RMPs need to follow these Guidelines while providing telemedicine consultation to patients. The Guidelines have been adopted as an amendment to the Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002 by adding regulation 3.8 titled as ‘Consultation by Telemedicine’ in the said regulations. In accordance with these regulations, the consultation through telemedicine by the RMPs under the IMC Act will be permissible in accordance with the Guidelines.


The Guidelines cover norms and standards for RMPs to consult patients via telemedicine. Telemedicine includes all channels of communication with the patient that leverage information technology platforms, including voice, audio, text, and digital data exchange (refer to our article at for more details on the Guidelines).


Registrations and Licenses for Telemedicine Centres/Clinics


RMPs are entitled to provide telemedicine consultation to patients from any part of India. However, if consultation centres or clinics are intended to be set up to deal with patients, their reports, primary care and in-person consultation and advice post discussions with doctors via telemedicine, the consultation centres or clinics would need compliance with certain central/state specific legislations.


The Central Government has enacted the Clinical Establishments (Registration and Regulation) Act, 2010 (“CE Act”) to provide for registration and regulation of all clinical establishments in India with a view to prescribe the minimum standards of facilities and services provided by such establishments. The term ‘clinical establishment’ has been defined widely under the CE Act and includes a hospital, maternity home, dispensary, clinic, diagnosis centre or an institution that offers services, facilities requiring diagnosis, treatment or care for illness, injury, deformity, abnormality, or pregnancy in any recognized system of medicine established and administered or maintained by any person or body of persons, whether incorporated or not.


Initially, the CE Act was applicable in the States of Arunachal Pradesh, Himachal Pradesh, Mizoram, Sikkim, and all Union Territories except the NCT of Delhi. Subsequently, the States of Uttar Pradesh, Uttarakhand, Rajasthan, Bihar, Jharkhand, Assam and Haryana have adopted the CE Act.


Considering that not all states have adopted the CE Act, many states such as Tamil Nadu, West Bengal, Karnataka have enacted state specific clinical establishments regulations. For instance, the Karnataka Private Medical Establishments Act, 2007 (“KPME Act”) provides for the regulation of private medical establishments in the State of Karnataka. Although the KPME Act does not expressly include ‘Telemedicine’ within its ambit, the KPME Act requires mandatory registration to establish or carry on any ‘private medical establishment’ which includes clinical laboratory, diagnostic centre, physiotherapy centre, clinic, polyclinic, consultation centre. A private medical establishment can be established, run or maintained in the State of Karnataka in accordance with the terms and conditions of registration granted under KPME Act. An application for registration is required to be made to the district registration authority with a fee of Rs. 1,500 (Rupees One Thousand and Five Hundred) if the centre is proposed to be uni-specality and Rs. 5,000 (Rupees Five Thousand) if the centre is proposed to be multi-specality. Registration is granted after satisfaction of the pre-requisites for registration.


Similarly, the Tamil Nadu Clinical Establishments (Regulation) Act, 1997 (“TNCE Act”) provides for the regulation of the clinical establishments in the State of Tamil Nadu. Although the TNCE Act does not expressly include ‘Telemedicine’ within its ambit, the TNCE Act requires mandatory registration to establish or carry on any ‘clinical establishment’ which incudes a dispensary, consulting room, clinic, polyclinic, or nursing home etc. An application for registration of the clinical establishment is required to be made in Form – 1 of the Tamil Nadu Clinical Establishments (Regulation) Rules, 2018. If the clinical establishment is offering services in more than one recognized system of medicine, separate applications would be required to be made for each such system of medicine such as Allopathy, Yoga, Naturopathy, Ayurveda, Homeopathy etc.


Miscellaneous Registrations and Licenses


Selling, stocking, exhibiting or offering for sale or distribution of drugs by the consultation centre or clinic post consultation with doctors via telemedicine would need to comply with the Drugs and Cosmetics Act, 1940 (“DC Act”) and the Drugs and Cosmetics Rules, 1945 (“DC Rules”). The consultation centre or clinic would need to seek a licence under the DC Act. An original licence or a renewed licence to sell drugs, unless suspended or cancelled, is valid for a period of five (5) years on and from the date on which it is granted or renewed. The form and categorization of the license to be obtained by the consultation centre or clinic under the DC Act and DC Rules is dependent on the drugs proposed to be dispensed at.


The Bio-Medical Waste Management Rules, 2016 (“BMWM Rules”) would also become applicable to the consultation centre or clinic if it generates, collects, receives, stores, disposes, or handles bio-medical waste in any form. The term ‘bio-medical waste’ includes any waste, generated during the diagnosis, treatment or immunization of human beings or animals or research activities pertaining thereto or in the production or testing of biological or in health camps including the categories of bio-medical waste mentioned in Schedule I appended to the BMWM Rules. The BMWM Rules requires the clinic to take all necessary steps to ensure that bio-medical waste is handled without any adverse effect to human health and the environment.


Considering that consultation via telemedicine would require exchange of personal and sensitive medical information about the patient, the collection and storage of such ‘personal information’ and ‘sensitive and personal data or information2’ would be regulated by the Information Technology (Reasonable Security Practices and Procedures and Sensitive Personal Data or Information) Rules, 2011 (“Data Protection Rules”), enacted pursuant to section 43A of the Information Technology Act, 2000 (“IT Act”). In terms of section 43A of the IT Act, if a body corporate possessing, dealing or handling any ‘sensitive personal data or information’ in a computer resource, which it owns, controls or operates, is negligent in implementing and maintaining reasonable security practices and procedures and thereby causes wrongful loss or wrongful gain to any person, such body corporate shall be liable to pay damages by way of compensation to the person so affected.


If the local consultation centres or clinics fall within the ambit of the definition of the term ‘clinical establishment’ under the applicable clinical establishment legislations, then the practice of telemedicine through centralized hub and state-wise consultation centres or clinics would need to comply with the above discussed regulations and many other ongoing compliances stipulated under the applicable legislations.




1 A person who is enrolled in the State Medical Register or the Indian Medical Register under the Indian Medical Council   Act 1956.


2 ‘Personal information’ as defined under the Data Protection Rules means any information that relates to a natural person, which, either directly or indirectly, in combination with other information available or likely to be available with a body corporate, is capable of identifying such person. Further, the term ‘sensitive personal data or information’ as defined under the Data Protection Rules means such personal information which consists of information relating to:


i.      password;

ii.     financial information such as bank account or credit card or debit card or other payment instrument details;

iii.    physical, physiological and mental health condition;

iv.    sexual orientation;

v.     medical records and history;

vi.    biometric information;

vii.   any detail relating to the above clauses as provided to body corporate for providing service; and

viii.   any of the information received under above clauses by body corporate for processing, stored or processed under lawful contract or otherwise.

If you have questions or would like additional information on the material covered herein, please contact:

Seema Jhingan, Partner

Abhijeet Das, Partner

Tanmay Mohanty, Associate

LexCounsel, Law Offices

B-4/232, Safdarjung Enclave

New Delhi 110 029, INDIA.

Tel.:+91.11.4166.2861 Fax:+91.11.4166.2862

Disclaimer: LexCounsel provides this e-update on a complimentary basis solely for informational purposes. It is not intended to constitute, and should not be taken as, legal advice, or a communication intended to solicit or establish any attorney-client relationship between LexCounsel and the reader(s). LexCounsel shall not have any obligations or liabilities towards any acts or omission of any reader(s) consequent to any information contained in this e-newsletter. The readers are advised to consult competent professionals in their own judgment before acting on the basis of any information provided hereby.

Popular posts from this blog

VC Interview: Shailendra Singh of Sequoia Capital India

In a recent interview to Venture Intelligence, Shailendra Singh discussed some of the firm’s newer investments in the early stage segment including in the online payments space, the progress at a few existing portfolio companies and the active role the firm is playing in helping its portfolio companies scale and succeed in India and globally. Prior to joining the firm in 2006, Singh was a strategy consultant at Bain & Company in New York and before that, an entrepreneur in the digital media industry. Venture Intelligence: How does Sequoia go about identifying potential early stage investments in India? Is there anything different you are doing today than, say, a couple of years back? Shailendra Singh: There is a lot more focus on technology investing and early stage investing. In general, as you might remember a few years ago, we were doing primarily growth investing but in the past 18-odd months, we have had a very strong focus on early stage and that’s continuing. In terms

ChrysCapital, Motilal Oswal PE & Sequoia named PE-VC Firms of the Decade

Press Release ChrysCapital, Motilal Oswal Private Equity and Sequoia Capital India have been named the top Private Equity & Venture Capital investors in India during the last decade, as part of Venture Intelligence’s APEX Awards. The Venture Intelligence “Awards for Private Equity Excellence” (APEX) is dedicated to celebrating the best that the Indian Private Equity & Venture Capital industry has to offer.  While ChrysCapital won the “Private Equity Investor of the Decade” award, Motilal Oswal Private Equity was feted as India’s “Growth Capital Investor of the Decade”. The Indian arm of the storied Silicon Valley VC firm, Sequoia Capital, was named the country’s “Venture Capital Investor of the Decade”. The APEX Awardees are selected based on both Self Nomination by the participating PE-VC firms as well as "crowd sourced" nominations and voting from the Limited Partner, PE-VC and advisory communities. (The main criteria were Exit Track Record, New Fund Raises & Fo

Ambit tops League Table for Transaction Advisors to Private Equity deals in 2019

Ambit Corporate Finance topped the Venture Intelligence League Table for Transaction Advisor to Private Equity Transactions for the year 2019. Ambit advised PE deals worth $2.4 Billion (across 4 qualifying transactions) during the period. Citi ($1.1 Billion across 2 deals) and  Avendus  ($969 million across 12 deals) took the second and third spot. Edelweiss Financial Services ($758 million across 9 deals) and  PwC  ($708 million across 15 deals) completed the top five in 2019.  The  Venture Intelligence League Tables , the first such initiative exclusively tracking transactions involving India-based companies, are based on value of PE and M&A transactions advised by Financial and Legal Advisory firms. Ambit Corporate Finance advised the $1.9 Billion buyout of Pipeline Infrastructure from Reliance Industries   by Brookfield Asset Management  and the IFC and I Squared Capital-backed   Cube Highways' acquisition of Delhi-Agra Toll Road from Reliance Infrastructu

Jio deals help PE investments climb 12% in H1'20 to $18.8 B

Press Release With Reliance Industries' communications unit Jio Platforms attracting 51% of the investment value, Private Equity-Venture Capital (PE-VC) investments in India rose 12% during the first 6 months of 2020 to $18.8 Billion (across 341 deals), shows data from  Venture Intelligence , a research service focused on private company financials, transactions and their valuations. Investments totaling over $9.5 Billion in Jio by a troop of global private equity firms, following social media giant Facebook's $5.7 Billion mid April investment in the company, helped overall PE-VC investments better the $16.8 Billion (across 503 transactions) invested during the same period in 2019. (Note: These figures include Venture Capital investments, but exclude PE investments in Real Estate).   Jio Platforms' $9.5 Billion Private Equity haul (excluding Facebook’s strategic investment) was led by Middle Eastern and American investors with KKR, Saudi Arabia's Public Invest

Inventus, Sixth Sense, Blume & Norwest win Apex'20 Venture Capital Awards

Inventus Capital Partners, Sixth Sense Ventures, Blume Ventures and Norwest Venture Partners were voted the top Venture Capital investors in India during 2019. The Venture Intelligence “Awards for Private Equity Excellence” (APEX) is dedicated to celebrating the best that the Indian Private Equity & Venture Capital industry has to offer. Other 2019 winners in the VC segment included  Axilor Ventures which was voted   the  Accelerator of the Year for the second year running, 3one4 Capital (VC Fund Raise of the Year) and Innoven Capital (Venture Debt firm of the Year). The APEX Awardees are selected based on both Self Nomination by the participating PE-VC firms as well as "crowd sourced" nominations and voting from the Limited Partner, PE-VC and advisory communities. (The main criteria are Exit Track Record, New Fund Raises & Follow-on Funding Rounds for Portfolio Companies).    " It is an honour to be recognised by entrepreneurs and investors as